Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49. https://doi.org/10.3322/caac.21820.

Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:1117–23. https://doi.org/10.1200/jco.2009.26.0133.

Article  PubMed  PubMed Central  Google Scholar 

Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, et al. Diagnostic performance of (18)F-DCFPyL-PET/CT in men with biochemically recurrent prostate Cancer: results from the CONDOR Phase III, Multicenter Study. Clin Cancer Res. 2021;27:3674–82. https://doi.org/10.1158/1078-0432.Ccr-20-4573.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16. https://doi.org/10.1016/s0140-6736(20)30314-7.

Article  CAS  PubMed  Google Scholar 

Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, et al. A phase 2/3 prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with (18)F-DCFPyL in prostate Cancer patients (OSPREY). J Urol. 2021;206:52–61. https://doi.org/10.1097/ju.0000000000001698.

Article  PubMed  PubMed Central  Google Scholar 

Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, et al. Diagnostic performance and safety of Positron Emission Tomography with (18)F-rhPSMA-7.3 in patients with newly diagnosed unfavourable Intermediate- to very-high-risk prostate Cancer: results from a phase 3, prospective, Multicentre Study (LIGHTHOUSE). Eur Urol. 2023;84:361–70. https://doi.org/10.1016/j.eururo.2023.06.018.

Article  CAS  PubMed  Google Scholar 

Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, et al. Diagnostic performance and safety of (18)F-rhPSMA-7.3 Positron Emission Tomography in Men with suspected prostate Cancer recurrence: results from a phase 3, prospective, Multicenter Study (SPOTLIGHT). J Urol. 2023;210:299–311. https://doi.org/10.1097/ju.0000000000003493.

Article  PubMed  Google Scholar 

Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148–63. https://doi.org/10.1016/j.eururo.2024.03.027.

Article  PubMed  Google Scholar 

de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of magnetic resonance imaging for local staging of prostate Cancer: a diagnostic Meta-analysis. Eur Urol. 2016;70:233–45. https://doi.org/10.1016/j.eururo.2015.07.029.

Article  PubMed  Google Scholar 

Wang F, Liu C, Vidal I, Mana-Ay M, Voter AF, Solnes LB, et al. Comparison of multiple segmentation methods for volumetric delineation of primary prostate Cancer with prostate-specific membrane Antigen-targeted (18)F-DCFPyL PET/CT. J Nucl Med. 2024;65:87–93. https://doi.org/10.2967/jnumed.123.266005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raveenthiran S, Yaxley WJ, Franklin T, Coughlin G, Roberts M, Gianduzzo T, et al. Findings in 1,123 men with preoperative (68)Ga-Prostate-specific membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to totally embedded radical prostatectomy histopathology: implications for the diagnosis and management of prostate Cancer. J Urol. 2022;207:573–80. https://doi.org/10.1097/ju.0000000000002293.

Article  CAS  PubMed  Google Scholar 

Ucar T, Gunduz N, Demirci E, Culpan M, Gunel H, Kir G, et al. Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: a retrospective study. Prostate. 2022;82:1462–8. https://doi.org/10.1002/pros.24420.

Article  CAS  PubMed  Google Scholar 

Chen M, Zhang Q, Zhang C, Zhou YH, Zhao X, Fu Y, et al. Comparison of (68)Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and multi-parametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer. Transl Androl Urol. 2020;9:382–90. https://doi.org/10.21037/tau.2020.03.06.

Article  PubMed  PubMed Central  Google Scholar 

Combes AD, Palma CA, Calopedos R, Wen L, Woo H, Fulham M, et al. PSMA PET-CT in the diagnosis and staging of prostate Cancer. Diagnostics (Basel). 2022;12. https://doi.org/10.3390/diagnostics12112594.

Leisenring W, Alonzo T, Pepe MS. Comparisons of predictive values of binary medical diagnostic tests for paired designs. Biometrics. 2000;56:345–51. https://doi.org/10.1111/j.0006-341x.2000.00345.x.

Article  CAS  PubMed  Google Scholar 

Soeterik TFW, van Melick HHE, Dijksman LM, Küsters-Vandevelde H, Stomps S, Schoots IG, et al. Development and External Validation of a Novel Nomogram to predict side-specific extraprostatic extension in patients with prostate Cancer undergoing radical prostatectomy. Eur Urol Oncol. 2022;5:328–37. https://doi.org/10.1016/j.euo.2020.08.008.

Article  PubMed  Google Scholar 

Martini A, Gupta A, Lewis SC, Cumarasamy S, Haines KG 3rd, Briganti A, et al. Development and internal validation of a side-specific, multiparametric magnetic resonance imaging-based nomogram for the prediction of extracapsular extension of prostate cancer. BJU Int. 2018;122:1025–33. https://doi.org/10.1111/bju.14353.

Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, et al. Head-to-Head comparison of (68)Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the detection, Intraprostatic Localization, and determination of local extension of primary prostate Cancer: results from a prospective single-center imaging trial. J Nucl Med. 2022;63:847–54. https://doi.org/10.2967/jnumed.121.262398.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grubmüller B, Baltzer P, Hartenbach S, D’Andrea D, Helbich TH, Haug AR, et al. PSMA Ligand PET/MRI for primary prostate Cancer: staging performance and clinical impact. Clin Cancer Res. 2018;24:6300–7. https://doi.org/10.1158/1078-0432.Ccr-18-0768.

Article  PubMed  Google Scholar 

Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane Antigen Positron Emission Tomography and Conventional Imaging modalities for initial staging of Intermediate- to high-risk prostate Cancer: a systematic review and Meta-analysis. Eur Urol. 2023;84:36–48. https://doi.org/10.1016/j.eururo.2023.03.001.

Article  PubMed  Google Scholar 

Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021;7:1635–42. https://doi.org/10.1001/jamaoncol.2021.3771.

Article  PubMed  PubMed Central  Google Scholar 

Weiner AB, Agrawal R, Valle LF, Sonni I, Kishan AU, Rettig MB, et al. Impact of PSMA PET on prostate Cancer Management. Curr Treat Options Oncol. 2024;25:191–205. https://doi.org/10.1007/s11864-024-01181-9.

Article  PubMed  PubMed Central  Google Scholar 

Sathekge M, Lengana T, Maes A, Vorster M, Zeevaart J, Lawal I, et al. (68)Ga-PSMA-11 PET/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-africans. Eur J Nucl Med Mol Imaging. 2018;45:226–34. https://doi.org/10.1007/s00259-017-3852-8.

Article  PubMed  Google Scholar